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Summary Zonisamide is an antiepilepsy drug (AED) with both sodium and calcium
channel-blocking properties. This dual mechanism may predict efﬁcacy in some re-
fractory patients, and a broad spectrum of action against different seizure types. Zon-
isamide has been commercially available in Japan since 1989, and became available
in the United States for treatment of adults over the age of 12 with partial—onset
seizures in March 2000. Several multicenter clinical trials have been conducted in
the United States over the past 15 years. These have included three double-blind,
placebo-controlled trials as well as long-term open-label studies. Zonisamide was
characterized in these studies as a safe and effective adjunctive treatment for partial-
onset seizures. Zonisamide has not yet been studied in the United States as an initial
monotherapy, but in one long-term study, some patients were able to discontinue
other AEDs and successfully transition to monotherapy. The most frequently reported
adverse events were somnolence, dizziness, and anorexia. Current United States la-
beling states that 12 patients with epilepsy receiving zonisamide had symptomatic
kidney stones; however, after more than a dozen years of zonisamide use in Japan,
the incidence of kidney stones associated with zonisamide remains low.
© 2004 Published by Elsevier Ltd on behalf of BEA Trading Ltd.
Introduction
Zonisamide is a structurally novel antiepilepsy drug
(AED) with a broad spectrum of antiseizure activ-
ity. At the cellular level, there are at least two
mechanisms of action, blockade of sustained ﬁr-
ing of voltage-sensitive sodium channels and reduc-
tion in voltage-dependent T-type calcium channel
currents.1,2
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Zonisamide has been available in Japan since
1989, where it is widely used both as monother-
apy and adjunctive therapy for various seizure
types and syndromes in adults and children. In the
United States, clinical trials of zonisamide began
in the early 1980s. These studies provided clear
evidence of zonisamide’s promise as an effective
adjunctive therapy for refractory partial seizures.
Leppik et al.3 observed a 52% reduction in seizure
frequency in a historical-control, open-label, mul-
ticenter study. However, development of kidney
stones in 3.7% of patients enrolled in this study
led to the temporary termination of US develop-
ment efforts. Testing resumed in the 1990s, and
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zonisamide was approved by the US Food and Drug
Administration (FDA) in March 2000 as adjunctive
treatment for partial-onset seizures in adults.
This article summarizes ﬁndings from key US clini-
cal trials carried out since 1984.4,5 A total of 810 pa-
tients have participated in these trials. The focus is
on ﬁndings from placebo-controlled and open-label
studies that have examined the drug’s short- and
long-term efﬁcacy and safety for the treatment of
refractory partial seizures.
Method
Tables 1 and 2 provide brief descriptions of key
US clinical trials. All study designs included a
dose-titration phase, usually 4 weeks in length,
with the exception of study 922 US, which used
4- and 8-week titration schedules. In long-term
extension studies, patients who had been on zon-
isamide treatment in a preceding short-term study
initially continued at the same dose; then, dose
adjustments were allowed to a maximum of 600mg
per day or to a target range of serum levels of
20—30g/mL, but not to exceed 40g/mL.
In all studies, primary and secondary efﬁcacy
variables were median percentage change from
baseline in seizure frequency and percentage of
responders, respectively. A responder was deﬁned
as any patient who experienced ≥50% reduction
from baseline seizure frequency. In all studies ex-
cept study 921, baseline seizure frequencies were
Table 1 Short-term, placebo-controlled clinical trials of zonisamide as adjunctive therapy in patients with
refractory partial seizures.
Study des-
ignation
Study descriptiona Study objectives
912 US • N = 152 Evaluate safety and efﬁcacy
• Placebo-controlled, parallel-group, randomized, double-blind
• 12-week baseline; 12-week treatment phase with 4-week
titration phase
• BID dosing
912 EU • N = 144 Evaluate safety and efﬁcacy
• Placebo-controlled, parallel-group, randomized, double-blind
• 12-week baseline; 12-week treatment phase with 4-week
titration phase
• QD dosing
922 US • N = 203 Evaluate safety and efﬁcacy at
ﬁxed incremental doses;
determine steady-state serum
levels
• Placebo-controlled, parallel-group, randomized, double-blind
• 4-week baseline phase; 20-week treatment phase with
4—8-week titration phase
a All three were multicenter, outpatient studies. Published reports of studies 912 US,6 912 EU,7 and 922 US8 present
slightly different analyses of study data than are reported herein.
determined based upon seizure diaries and com-
munication between investigators and patients or
caregivers. In study 921, baseline seizure frequen-
cies were determined more informally, based on
patient or investigator recall. For long-term studies
912 US EXT and 912 EU EXT, changes in seizure fre-
quencies and response rates were calculated using
baseline seizure frequencies from the preceding
short-term study.
The safety of zonisamide was assessed primarily
in terms of treatment-emergent adverse events.
Results from clinical laboratory evaluations and
other tests, including renal ultrasonograms, were
also taken into consideration. In some studies, data
on serum levels of zonisamide were analyzed to
identify possible correlations with efﬁcacy mea-
sures and adverse effects.
Results
Short-term, placebo-controlled studies
Patient demographics
Patients in these studies ranged in age from 12 to
79 years. In placebo-controlled trials, patients in
placebo and treatment groups were generally com-
parable in age, weight, height, race, seizure type,
and baseline seizure frequency. In study 912 US, the
number of male patients enrolled was considerably
higher than that of females, but statistical analyses
revealed no signiﬁcant effect of gender on efﬁcacy.
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Table 2 Long-term clinical trials of zonisamide as adjunctive therapy in patients with refractory partial seizures.
Study designation Study descriptiona Study objectives
912 US EXT • N = 123 Evaluate long-term safety and efﬁcacy
• Patients enrolled after 912 US;
long-term treatment up to 18 months
or more (range: 1—39 months)
912 EU EXT • N = 115 Evaluate long-term safety and efﬁcacy
• Patients enrolled after 912 EU;
long-term treatment up to 18 months
or more (range: <1—34 months)
920 • N = 103 Evaluate long-term safety and efﬁcacy
• 12-week baseline followed by a
4-week titration, a 12-week treatment
phase, and a long-term treatment
phase up to 24 months
921 • N = 208 Evaluate long-term safety and efﬁcacy;
examine efﬁcacy as monotherapy
following withdrawal of concomitant AED
• 24-week treatment phase including
4-week dose titration phase, and
20-week continued-treatment phase;
long-term therapy up to 24 months
a All studies were multicenter, outpatient, open-label; all studies were baseline-controlled except 921, which was
historical-controlled.
Efﬁcacy results
Efﬁcacy ﬁndings from the three placebo-controlled
studies are summarized in Figs. 1 and 2. Fig. 1
shows that patients who took zonisamide at dosages
of 400—600mg per day as an add-on to existing
AEDs experienced a median reduction in all partial
seizures of 27.2, 29.6, and 40.5% for studies 912
EU, 912 US, and 922 US, respectively. These values
differed signiﬁcantly from placebo values of −1.1%
(912 EU; P < 0.05), −3.3% (912 US; P < 0.0001),
and 9.0% (922 US; P = 0.0082). Assessment of the
percentage of responders also demonstrated that
Figure 1 Reduction in seizure frequency with zon-
isamide treatment in placebo-controlled studies. All par-
tial seizures; zonisamide doses 400–600mg per day. *The
differences from placebo were statistically signiﬁcant
(P < 0.05).
zonisamide effectively reduced seizures relative to
placebo (Fig. 2).
Protocols for the three placebo-controlled stud-
ies differed in several ways, including the man-
ner in which zonisamide was introduced. In study
912 US and 912 EU, patients who received zon-
isamide were given the drug at dosages of 100mg
per day the ﬁrst week, 200mg per day the second
week, and 400mg per day for weeks 3 and 4. Af-
ter week 4, dosages could be adjusted as necessary
to a maximum dosage of 20mg/kg per day or to
a maximum plasma level of 40g/mL. In contrast,
Figure 2 Percentage responders to zonisamide in
short-term studies. Responder rates for all partial
seizures; zonisamide doses 400–600mg per day. *The
differences from placebo were statistically signiﬁcant
(P < 0.05).
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Figure 3 Efﬁcacy of zonisamide at low dosages. Results
are from study 922 US, all partial seizures. Differences
from placebo were statistically signiﬁcant (P < 0.05).
patients in study 922 US received zonisamide in
one of three dose escalation regimens. One group
received 100mg per day for 5 weeks, 200mg per
day for 1 week, 300mg per day for 1 week, and
400mg per day for 13 weeks. The second group
received 100mg per day for 1 week, 200mg per
day for 5 weeks, 300mg per day for 1 week, and
400mg per day for 13 weeks. The third group re-
ceived placebo for 12 weeks, 100mg per day for
1 week, 200mg per day for 1 week, 300mg per
day for 1 week, and 400mg per day for 5 weeks.
This design permitted examination of efﬁcacy at
low zonisamide doses during the titration phase of
the study. Study 922 US results showed that a sig-
niﬁcant therapeutic beneﬁt was obtained even at
100mg per day (24.7% reduction in partial seizure
frequency with zonisamide compared to 8.3% re-
duction with placebo; P = 0.0389) (Fig. 3). Results
at 200mg per day also showed signiﬁcant improve-
ment relative to placebo, 23% reduction versus 4%
for placebo (P = 0.0023) (Fig. 3).
Safety and tolerability results
Zonisamide was well tolerated in the short-term,
placebo-controlled studies. Adverse events most
often involved effects on the nervous system; those
reported most frequently by patients in the two US
placebo-controlled trials are shown in Table 3. In
considering these results, it is important to note
that all patients were receiving at least one addi-
tional AED in addition to study drug or placebo, and
about half were receiving two. Moreover, adverse
events were notably higher in most categories
when titration was more rapid (as in study 912 US),
than when titration was slower (as in study 922 US).
With slower titration, only dizziness, somnolence,
anorexia, accidental injury, headache, infection,
and nausea occurred in ≥10% of patients in the
zonisamide group (Table 3), and only the incidence
of anorexia was signiﬁcantly higher than in the
placebo group. The frequency of adverse events
in study 922 US declined during weeks 13—20 of
treatment, suggesting that patients develop tol-
erance to these adverse events. Clinical labora-
tory evaluations revealed no changes of clinical
consequence.
Few adverse events were classiﬁed as seri-
ous. Among the serious adverse events, few
were considered zonisamide-related or possibly
zonisamide-related; most commonly rash, in-
creased seizures, and kidney stones. Four patients
in 922 US had possible renal calculi during the
20-week treatment period. These were all sus-
pected by ultrasound, none were symptomatic, and
zonisamide was not discontinued in any patient be-
cause of a suspicious ultrasound ﬁnding. No kidney
stones occurred among patients in study 912 US or
912 EU.
Serum levels of zonisamide
Serum levels during study 922 US bore a roughly lin-
ear relationship to dosage. Dosages of 200mg per
day producedmean serum concentrations that were
approximately twice that of patients taking 100mg
per day (6.94g/mL versus 3.64g/mL), but mean
serum concentrations at dosages of ≥400mg per
day were in the range of 16.32—21.77g/mL. The
slightly lower than expected concentrations at
lower dosages may have been due to erythrocyte
binding of zonisamide, a less signiﬁcant factor at
the 400mg dose. Reduction in partial seizure fre-
quency at the lower zonisamide dosages, 100 and
200mg per day, did not correlate with increasing
serum concentrations, with 3.64g/mL associated
with a median reduction of 24.7%, and 6.94g/mL
associated with a median reduction of 23.0%. The
400mg per day dosage, however, produced a me-
dian reduction of 40.5%. In studies 912 US and 922
US, no differences were observed when serum zon-
isamide levels among responders were compared
with those of nonresponders. This phenomenon has
been observed with studies of other AEDs and prob-
ably reﬂects biological differences in the severity
of epilepsy between patients rather than a true lack
of correlation between dose and response for indi-
vidual patients. No clear relationship was observed
between serum concentrations and the percentage
of patients experiencing adverse events.
Long-term studies
Patient demographics
Patients in studies 912 US EXT, 912 EU EXT, 920,
and 921 ranged in age from 12 to 79 years. Per-
centages of males and females in each study were
approximately equal, with the exception of 912 US
EXT, which included about twice as many males as
Review of United States and European clinical trials of zonisamide S63
Table 3 Treatment-emergent adverse eventsa.
Adverse event Percentage of patients affected
912 US: 4-week titration 922 US: 8-week titration (100 and
200mg per day dosages)
Zonisamide (n = 78) Placebo (n = 74) Zonisamide (n = 118) Placebo (n = 85)
Accidental injury 5.1 2.7 13.6 11.8
Agitation/irritability 23.1 6.8 5.9 7.1
Anorexia 24.4 8.1 14.4 9.4
Ataxia 17.9 5.4 5.1 2.4
Confusion 14.1 4.1 5.1 7.1
Depression 11.5 1.4 6.8 5.9
Difﬁculty concentrating 15.4 4.1 3.4 1.2
Difﬁculty with memory 12.8 2.7 5.1 3.5
Diplopia 16.7 6.8 6.8 5.9
Dizziness 24.4 17.6 16.9 14.1
Fatigue 15.4 4.1 8.5 11.8
Headache 19.2 10.8 12.7 12.9
Infection 6.4 5.4 11.0 16.5
Insomnia 12.8 2.7 6.8 7.1
Mental slowing 11.5 2.7 3.4 2.4
Nausea 17.9 13.5 10.2 9.4
Paresthesia 11.5 1.4 2.5 3.5
Somnolence 38.5 13.5 15.3 14.1
Speech abnormalities 10.3 1.4 6.8 4.7
Tiredness 15.4 10.8 4.2 8.2
a Adverse events seen in ≥10% of patients in either treatment group of studies 912 US and 922 US.
females. The median baseline frequency of all par-
tial seizures ranged from 7.4 per month (921) to 9.8
per month (912 US EXT).
Efﬁcacy ﬁndings
In the long-term studies, the median percentage re-
duction from baseline in all partial seizures ranged
from 13.9% (921) to 50.1% (912 US EXT) (Fig. 4).
The proportion of patients who were classiﬁed as
responders ranged from 28.1% (921) to 55% (912 EU
EXT).
Comparison of patient responses in 912 US and
912 EU with data from their respective extension
Figure 4 Median percentage reduction in seizures with
zonisamide from long-term studies. All partial seizures.
studies shows that efﬁcacy was maintained or pos-
sibly improved over time. For example, median
reductions for all partial seizures for 912 US and
912 EU were 29.6 and 27.2%, respectively; with
long-term treatment in study 912 US EXT and 912
EU EXT, median reductions were 50.1 and 45.4%,
respectively. Studies 920 and 921 also compared
responses during the initial weeks of treatment
and over longer intervals (up to 24 months). In 920,
short-term treatment (weeks 5—16) yielded a 35.8%
reduction in all partial seizures; with long—term
treatment (2—24 months), the overall reduction
was 37.9%. In study 921, zonisamide treatment pro-
duced an 11.2% reduction in partial seizures over
weeks 5—24 and a 13.9% reduction over months
7—24. The lower efﬁcacy observed in study 921 may
be related to inaccuracies in baseline seizure fre-
quencies determined based on recall information.
Collectively, the data suggest that most patients
who take zonisamide over long periods of time do
not develop tolerance to the anticonvulsant effects
of the drug.
Zonisamide as monotherapy
An objective of study 921 was to reduce the
dosage of concomitant AEDs, or to eliminate them
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altogether, while maintaining seizure control. For
many patients, the dosage of concomitant AEDs
was successfully reduced, and for 10 patients,
concomitant AEDs were completely withdrawn for
periods ranging from 6 to 140 weeks. Four of these
patients achieved a seizure reduction of ≥50%,
and therefore were considered responders to zon-
isamide monotherapy at dosages of 400—600mg
per day. Three patients remained on monotherapy
through the end of the study, 140 weeks.
Safety and tolerability results
Treatment-emergent adverse events with long-term
treatment were similar to those observed during
short-term treatment, but their incidence declined
with time. In study 920, treatment-emergent ad-
verse events observed with short-term treatment
included dizziness (27.2%), somnolence (27.2%),
fatigue (23.3%), anorexia (21.4%), rhinitis (21.4%),
and nausea (19.4%). With the exception of rhinitis,
the percentage of patients experiencing these ad-
verse events declined sharply with long-term treat-
ment, with the percentage of patients reporting
dizziness dropping to 12.9%; somnolence, to 7.1%;
fatigue, to 3.5%; anorexia, to 7.1%, and nausea, to
10.6%. Investigators considered some of these ad-
verse events, including fatigue, anorexia, and nau-
sea, to be ‘‘deﬁnitely’’ attributable to zonisamide.
In study 921, adverse events most frequently
reported during weeks 1—24 were somnolence,
rhinitis, fatigue, nausea or vomiting, dizziness,
ataxia, and anorexia. With the exception of rhini-
tis, the frequency with which patients reported
these events declined with long-term zonisamide
use. Of all reported adverse events, investigators
ranked 66.6% as mild, 29.1% as moderate, and 4.2%
as severe. Among adverse events rated as severe
were migraine (two occurrences), anorexia (two
occurrences), somnolence (three occurrences),
status epilepticus (seven occurrences), and renal
colic (two occurrences). About 6% of patients ex-
perienced adverse events that were considered by
the investigator to be ‘‘deﬁnitely’’ attributable to
zonisamide; the majority (≥75%) were classiﬁed as
‘‘possibly’’ related or ‘‘unrelated’’ to the study
medication.
The incidence of clinically symptomatic kidney
stones increased with long-term treatment. Among
all studies, 15 of 549 patients (2.7%) had kidney
stones (Table 4), and percentages of patients af-
fected ranged from 1.6% (912 US) to 4.9% (920).
The mean study day of onset ranged from day 174
(study 912 EU EXT) to day 684 (study 912 US EXT).
Most cases of renal calculi were characterized by
investigators as ‘‘possibly’’ related to zonisamide
treatment. Only two patients, one in study 912 US
Table 4 Incidence of kidney stones in long-term
studies.
Study n/N Percentage Mean study
day of onset
(range)
912 US EXT 2/123 1.6 684 (506—862)
912 EU EXT 2/115 1.7 174 (101—248)
920 5/103 4.9 579 (195—729)
921 6/208 2.9 390 (124—821)
Overall 15/549 2.7 —
EXT and one in study 920, discontinued zonisamide
treatment because of kidney stones. The rash rate
among all these studies was notably low at 4%, and
no serious skin-related adverse events occurred.
Discussion and conclusions
Results from placebo-controlled, short-term stud-
ies, as well as baseline- or historical-controlled,
long-term studies, demonstrate that zonisamide
is an effective adjunctive treatment for refrac-
tory partial-onset seizures. Zonisamide efﬁcacy
did not decline over time, suggesting that most
patients do not develop tolerance to the anticon-
vulsant effects of zonisamide. Findings from one
of the long-term studies indicate that, for some
patients, zonisamide can be effective as monother-
apy. Zonisamide was well-tolerated; most adverse
events were mild to moderate, and their inci-
dence declined as treatment continued. The few
serious adverse events were all reversible with
zonisamide dose reduction or discontinuation or
the passage of time. US clinical trials show that
zonisamide is a safe and effective AED for the
treatment of refractory partial-onset seizures. Fur-
ther studies are needed to establish monotherapy
efﬁcacy.
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